Format

Send to

Choose Destination
Med Oncol. 2013 Dec;30(4):757. doi: 10.1007/s12032-013-0757-7. Epub 2013 Oct 31.

Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Author information

1
Translational Cancer Research, Lund University, Medicon Village, Building 404:C3, 223 63, Lund, Sweden, Kazi.Uddin@med.lu.se.

Abstract

Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment.

PMID:
24174318
DOI:
10.1007/s12032-013-0757-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center